[ad_1] The defendants in a defamation lawsuit brought by Cassava Sciences have hit back at…
Tag:
Biopharmaceuticals
-
-
STOCK MARKET
Pfizer sets new prices for its COVID-19 vaccines. The cost? $110 to $130 per dose
by userby user[ad_1] Pfizer Inc. PFE, +4.75% said Thursday that it plans to sell the COVID-19 shot…
-
STOCK MARKET
Fresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
by userby user[ad_1] A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and…
-
STOCK MARKET
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11
by userby user[ad_1] Pfizer and German partner BioNTech said Monday they’re seeking Food and Drug Administration authorization…
-
STOCK MARKET
Market rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff
by userby user[ad_1] At least two initial public offerings were withdrawn during Tuesday’s brutal stock market rout,…
-
STOCK MARKET
Moderna sets up clash with Pfizer and BioNTech with patent lawsuits in the U.S. and Germany
by userby user[ad_1] Moderna Inc. on Friday filed lawsuits against Pfizer Inc. and German partner BioNTech SE,…
-
[ad_1] Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it…
-
STOCK MARKET
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
by userby user[ad_1] Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor…
-
STOCK MARKET
Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says
by userby user[ad_1] AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression…
-
STOCK MARKET
Celcuity stock soars after hours on breakthrough therapy designation for cancer drug
by userby user[ad_1] Shares of Celcuity Inc. CELC, -0.75% were up 17% at $10.80 after hours as…